| Human immunodeficiency virus I infection
Edurant vs Sunlenca
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Edurant vs Sunlenca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSunlenca has a higher rate of injection site reactions vs Edurant based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sunlenca but not Edurant, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Edurant
Sunlenca
At A Glance
Oral
Once daily
Non-nucleoside reverse transcriptase inhibitor (NNRTI)
SC injection
Every 6 months
HIV-1 capsid inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 25 mg oral tablet once daily with a meal for patients weighing at least 25 kg. Pediatric patients 2 years and older weighing 14-20 kg receive 12.5 mg (5 x 2.5 mg dispersed tablets); 20-25 kg receive 15 mg (6 x 2.5 mg dispersed tablets). During pregnancy with virologic suppression, 25 mg once daily with a meal. When coadministered with rifabutin, increase to 50 mg (two 25 mg tablets) once daily with a meal.
Human immunodeficiency virus I infection (Initiation Option 1) Day 1: 927 mg SC injection (2 x 1.5 mL) plus 600 mg oral (2 x 300 mg tablets); Day 2: 600 mg oral (2 x 300 mg tablets); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (Initiation Option 2) Days 1 and 2: 600 mg oral (2 x 300 mg tablets); Day 8: 300 mg oral (1 x 300 mg tablet); Day 15: 927 mg SC injection (2 x 1.5 mL); then 927 mg SC every 6 months (26 weeks) for maintenance.
Contraindications
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (more than single-dose treatment)
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
- Concomitant use of strong CYP3A inducers
Adverse Reactions
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, rash, dizziness, nausea, abdominal pain, vomiting, fatigue
Serious Skin and hypersensitivity reactions including DRESS, hepatotoxicity, depressive disorders
Postmarketing Nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS
Most common (>=3%) Injection site reactions, nausea
Serious Grade 3 injection site reactions (erythema, pain, swelling)
Postmarketing Injection site necrosis
Pharmacology
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Lenacapavir is a multistage, selective HIV-1 capsid inhibitor that directly binds to capsid protein (p24) subunits in hexamers, inhibiting multiple essential steps of the viral lifecycle including capsid-mediated nuclear uptake of proviral DNA, virus assembly and release, and capsid core formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Edurant
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (11/12)
Sunlenca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Edurant
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Sunlenca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Edurant
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Sunlenca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Gilead Advancing Access Co-Pay Program: SunlencaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EdurantView full Edurant profile
SunlencaView full Sunlenca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.